Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Association between genetically predicted polycystic ovary syndrome and ovarian cancer: a Mendelian randomization study.

Harris HR, Cushing-Haugen KL, Webb PM, Nagle CM, Jordan SJ; Australian Ovarian Cancer Study Group, Risch HA, Rossing MA, Doherty JA, Goodman MT, Modugno F, Ness RB, Moysich KB, Kjær SK, Høgdall E, Jensen A, Schildkraut JM, Berchuck A, Cramer DW, Bandera EV, Rodriguez L, Wentzensen N, Kotsopoulos J, Narod SA, McLaughlin JR, Anton-Culver H, Ziogas A, Pearce CL, Wu AH, Lindström S, Terry KL.

Int J Epidemiol. 2019 Jun 1;48(3):822-830. doi: 10.1093/ije/dyz113.

PMID:
31211375
2.

Histotype classification of ovarian carcinoma: A comparison of approaches.

Peres LC, Cushing-Haugen KL, Anglesio M, Wicklund K, Bentley R, Berchuck A, Kelemen LE, Nazeran TM, Gilks CB, Harris HR, Huntsman DG, Schildkraut JM, Rossing MA, Köbel M, Doherty JA.

Gynecol Oncol. 2018 Oct;151(1):53-60. doi: 10.1016/j.ygyno.2018.08.016. Epub 2018 Aug 16.

3.

Invasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage.

Peres LC, Cushing-Haugen KL, Köbel M, Harris HR, Berchuck A, Rossing MA, Schildkraut JM, Doherty JA.

J Natl Cancer Inst. 2019 Jan 1;111(1):60-68. doi: 10.1093/jnci/djy071.

4.

Lifestyle factors and subsequent ischemic heart disease risk after hematopoietic cell transplantation.

Leger KJ, Baker KS, Cushing-Haugen KL, Flowers MED, Leisenring WM, Martin PJ, Mendoza JA, Reding KW, Syrjala KL, Lee SJ, Chow EJ.

Cancer. 2018 Apr 1;124(7):1507-1515. doi: 10.1002/cncr.31227. Epub 2018 Jan 9.

5.

Morbidity and Mortality Differences Between Hematopoietic Cell Transplantation Survivors and Other Cancer Survivors.

Chow EJ, Cushing-Haugen KL, Cheng GS, Boeckh M, Khera N, Lee SJ, Leisenring WM, Martin PJ, Mueller BA, Schwartz SM, Baker KS.

J Clin Oncol. 2017 Jan 20;35(3):306-313. doi: 10.1200/JCO.2016.68.8457. Epub 2016 Nov 21.

6.

Risk Prediction for Epithelial Ovarian Cancer in 11 United States-Based Case-Control Studies: Incorporation of Epidemiologic Risk Factors and 17 Confirmed Genetic Loci.

Clyde MA, Palmieri Weber R, Iversen ES, Poole EM, Doherty JA, Goodman MT, Ness RB, Risch HA, Rossing MA, Terry KL, Wentzensen N, Whittemore AS, Anton-Culver H, Bandera EV, Berchuck A, Carney ME, Cramer DW, Cunningham JM, Cushing-Haugen KL, Edwards RP, Fridley BL, Goode EL, Lurie G, McGuire V, Modugno F, Moysich KB, Olson SH, Pearce CL, Pike MC, Rothstein JH, Sellers TA, Sieh W, Stram D, Thompson PJ, Vierkant RA, Wicklund KG, Wu AH, Ziogas A, Tworoger SS, Schildkraut JM; , on behalf of the Ovarian Cancer Association Consortium.

Am J Epidemiol. 2016 Oct 15;184(8):579-589. Epub 2016 Oct 3. Erratum in: Am J Epidemiol. 2017 Jul 1;186(1):130.

7.

Association Between Menopausal Estrogen-Only Therapy and Ovarian Carcinoma Risk.

Lee AW, Ness RB, Roman LD, Terry KL, Schildkraut JM, Chang-Claude J, Doherty JA, Menon U, Cramer DW, Gayther SA, Risch H, Gentry-Maharaj A, Goodman MT, Modugno F, Eilber U, Moysich KB, Berchuck A, Rossing MA, Jensen A, Wicklund KG, Cushing-Haugen KL, Hogdall E, Rudolph A, Thompson PJ, Wilkens LR, Kjaer SK, Carney ME, Stram DO, Ramus SJ, Wu AH, Pike MC, Pearce CL; Ovarian Cancer Association Consortium.

Obstet Gynecol. 2016 May;127(5):828-36. doi: 10.1097/AOG.0000000000001387.

8.

Corrigendum: Common variants at 19p13 are associated with susceptibility to ovarian cancer.

Bolton KL, Tyrer J, Song H, Ramus SJ, Notaridou M, Jones C, Sher T, Gentry-Maharaj A, Wozniak E, Tsai YY, Weidhaas J, Paik D, Van Den Berg DJ, Stram DO, Pearce CL, Wu AH, Brewster W, Anton-Culver H, Ziogas A, Narod SA, Levine DA, Kaye SB, Brown R, Paul J, Flanagan J, Sieh W, McGuire V, Whittemore AS, Campbell I, Gore ME, Lissowska J, Yang HP, Medrek K, Gronwald J, Lubinski J, Jakubowska A, Le ND, Cook LS, Kelemen LE, Brooks-Wilson A, Massuger LF, Kiemeney LA, Aben KK, van Altena AM, Houlston R, Tomlinson I, Palmieri RT, Moorman PG, Schildkraut J, Iversen ES, Phelan C, Vierkant RA, Cunningham JM, Goode EL, Fridley BL, Kruger-Kjaer S, Blaeker J, Hogdall E, Hogdall C, Gross J, Karlan BY, Ness RB, Edwards RP, Odunsi K, Moyisch KB, Baker JA, Modugno F, Heikkinenen T, Butzow R, Nevanlinna H, Leminen A, Bogdanova N, Antonenkova N, Doerk T, Hillemanns P, Dürst M, Runnebaum I, Thompson PJ, Carney ME, Goodman MT, Lurie G, Wang-Gohrke S, Hein R, Chang-Claude J, Rossing MA, Cushing-Haugen KL, Doherty J, Chen C, Rafnar T, Besenbacher S, Sulem P, Stefansson K, Birrer MJ, Terry KL, Hernandez D, Cramer DW, Vergote I, Amant F, Lambrechts D, Despierre E, Fasching PA, Beckmann MW, Thiel FC, Ekici AB, Chen X; Australian Ovarian Cancer Study Group, Johnatty SE, Webb PM, Beesley J, Chanock S, Garcia-Closas M, Sellers T, Easton DF, Berchuck A, Chenevix-Trench G, Pharoah PD, Gayther SA.

Nat Genet. 2016 Jan;48(1):101. doi: 10.1038/ng0116-101b. No abstract available.

PMID:
26711112
9.

The risk of breast cancer associated with specific patterns of migraine history.

Lowry SJ, Malone KE, Cushing-Haugen KL, Li CI.

Cancer Causes Control. 2014 Dec;25(12):1707-15. doi: 10.1007/s10552-014-0479-y. Epub 2014 Oct 31.

10.

Plasma choline metabolites and colorectal cancer risk in the Women's Health Initiative Observational Study.

Bae S, Ulrich CM, Neuhouser ML, Malysheva O, Bailey LB, Xiao L, Brown EC, Cushing-Haugen KL, Zheng Y, Cheng TY, Miller JW, Green R, Lane DS, Beresford SA, Caudill MA.

Cancer Res. 2014 Dec 15;74(24):7442-52. doi: 10.1158/0008-5472.CAN-14-1835. Epub 2014 Oct 21.

11.

Late cardiovascular complications after hematopoietic cell transplantation.

Chow EJ, Wong K, Lee SJ, Cushing-Haugen KL, Flowers ME, Friedman DL, Leisenring WM, Martin PJ, Mueller BA, Baker KS.

Biol Blood Marrow Transplant. 2014 Jun;20(6):794-800. doi: 10.1016/j.bbmt.2014.02.012. Epub 2014 Feb 22.

12.

Influence of conventional cardiovascular risk factors and lifestyle characteristics on cardiovascular disease after hematopoietic cell transplantation.

Chow EJ, Baker KS, Lee SJ, Flowers ME, Cushing-Haugen KL, Inamoto Y, Khera N, Leisenring WM, Syrjala KL, Martin PJ.

J Clin Oncol. 2014 Jan 20;32(3):191-8. doi: 10.1200/JCO.2013.52.6582. Epub 2013 Dec 2.

13.

Long-term statin use and risk of ductal and lobular breast cancer among women 55 to 74 years of age.

McDougall JA, Malone KE, Daling JR, Cushing-Haugen KL, Porter PL, Li CI.

Cancer Epidemiol Biomarkers Prev. 2013 Sep;22(9):1529-37. doi: 10.1158/1055-9965.EPI-13-0414. Epub 2013 Jul 5.

14.

Nightshift work and risk of ovarian cancer.

Bhatti P, Cushing-Haugen KL, Wicklund KG, Doherty JA, Rossing MA.

Occup Environ Med. 2013 Apr;70(4):231-7. doi: 10.1136/oemed-2012-101146. Epub 2013 Jan 23.

15.

Sun exposure and risk of epithelial ovarian cancer.

Bodelon C, Cushing-Haugen KL, Wicklund KG, Doherty JA, Rossing MA.

Cancer Causes Control. 2012 Dec;23(12):1985-94. doi: 10.1007/s10552-012-0076-x. Epub 2012 Oct 12.

16.

Breast-feeding and risk of epithelial ovarian cancer.

Jordan SJ, Cushing-Haugen KL, Wicklund KG, Doherty JA, Rossing MA.

Cancer Causes Control. 2012 Jun;23(6):919-27. doi: 10.1007/s10552-012-9963-4. Epub 2012 Apr 24.

17.

Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies.

Pearce CL, Templeman C, Rossing MA, Lee A, Near AM, Webb PM, Nagle CM, Doherty JA, Cushing-Haugen KL, Wicklund KG, Chang-Claude J, Hein R, Lurie G, Wilkens LR, Carney ME, Goodman MT, Moysich K, Kjaer SK, Hogdall E, Jensen A, Goode EL, Fridley BL, Larson MC, Schildkraut JM, Palmieri RT, Cramer DW, Terry KL, Vitonis AF, Titus LJ, Ziogas A, Brewster W, Anton-Culver H, Gentry-Maharaj A, Ramus SJ, Anderson AR, Brueggmann D, Fasching PA, Gayther SA, Huntsman DG, Menon U, Ness RB, Pike MC, Risch H, Wu AH, Berchuck A; Ovarian Cancer Association Consortium.

Lancet Oncol. 2012 Apr;13(4):385-94. doi: 10.1016/S1470-2045(11)70404-1. Epub 2012 Feb 22.

18.

Cardiovascular hospitalizations and mortality among recipients of hematopoietic stem cell transplantation.

Chow EJ, Mueller BA, Baker KS, Cushing-Haugen KL, Flowers ME, Martin PJ, Friedman DL, Lee SJ.

Ann Intern Med. 2011 Jul 5;155(1):21-32. doi: 10.7326/0003-4819-155-1-201107050-00004.

PMID:
21727290
19.

Genital powder exposure and the risk of epithelial ovarian cancer.

Rosenblatt KA, Weiss NS, Cushing-Haugen KL, Wicklund KG, Rossing MA.

Cancer Causes Control. 2011 May;22(5):737-42. doi: 10.1007/s10552-011-9746-3. Epub 2011 Mar 10.

20.

Genetic variation in insulin-like growth factor 2 may play a role in ovarian cancer risk.

Pearce CL, Doherty JA, Van Den Berg DJ, Moysich K, Hsu C, Cushing-Haugen KL, Conti DV, Ramus SJ, Gentry-Maharaj A, Menon U, Gayther SA, Pharoah PD, Song H, Kjaer SK, Hogdall E, Hogdall C, Whittemore AS, McGuire V, Sieh W, Gronwald J, Medrek K, Jakubowska A, Lubinski J, Chenevix-Trench G; AOCS/ACS Study Group, Beesley J, Webb PM, Berchuck A, Schildkraut JM, Iversen ES, Moorman PG, Edlund CK, Stram DO, Pike MC, Ness RB, Rossing MA, Wu AH.

Hum Mol Genet. 2011 Jun 1;20(11):2263-72. doi: 10.1093/hmg/ddr087. Epub 2011 Mar 21.

21.

Relationship between menopausal symptoms and risk of postmenopausal breast cancer.

Huang Y, Malone KE, Cushing-Haugen KL, Daling JR, Li CI.

Cancer Epidemiol Biomarkers Prev. 2011 Feb;20(2):379-88. doi: 10.1158/1055-9965.EPI-10-0998. Epub 2011 Jan 6.

22.

Common variants at 19p13 are associated with susceptibility to ovarian cancer.

Bolton KL, Tyrer J, Song H, Ramus SJ, Notaridou M, Jones C, Sher T, Gentry-Maharaj A, Wozniak E, Tsai YY, Weidhaas J, Paik D, Van Den Berg DJ, Stram DO, Pearce CL, Wu AH, Brewster W, Anton-Culver H, Ziogas A, Narod SA, Levine DA, Kaye SB, Brown R, Paul J, Flanagan J, Sieh W, McGuire V, Whittemore AS, Campbell I, Gore ME, Lissowska J, Yang HP, Medrek K, Gronwald J, Lubinski J, Jakubowska A, Le ND, Cook LS, Kelemen LE, Brooks-Wilson A, Massuger LF, Kiemeney LA, Aben KK, van Altena AM, Houlston R, Tomlinson I, Palmieri RT, Moorman PG, Schildkraut J, Iversen ES, Phelan C, Vierkant RA, Cunningham JM, Goode EL, Fridley BL, Kruger-Kjaer S, Blaeker J, Hogdall E, Hogdall C, Gross J, Karlan BY, Ness RB, Edwards RP, Odunsi K, Moyisch KB, Baker JA, Modugno F, Heikkinenen T, Butzow R, Nevanlinna H, Leminen A, Bogdanova N, Antonenkova N, Doerk T, Hillemanns P, Dürst M, Runnebaum I, Thompson PJ, Carney ME, Goodman MT, Lurie G, Wang-Gohrke S, Hein R, Chang-Claude J, Rossing MA, Cushing-Haugen KL, Doherty J, Chen C, Rafnar T, Besenbacher S, Sulem P, Stefansson K, Birrer MJ, Terry KL, Hernandez D, Cramer DW, Vergote I, Amant F, Lambrechts D, Despierre E, Fasching PA, Beckmann MW, Thiel FC, Ekici AB, Chen X; Australian Ovarian Cancer Study Group; Australian Cancer Study (Ovarian Cancer); Ovarian Cancer Association Consortium, Johnatty SE, Webb PM, Beesley J, Chanock S, Garcia-Closas M, Sellers T, Easton DF, Berchuck A, Chenevix-Trench G, Pharoah PD, Gayther SA.

Nat Genet. 2010 Oct;42(10):880-4. doi: 10.1038/ng.666. Epub 2010 Sep 19. Erratum in: Nat Genet. 2016 Jan;48(1):101. Brook-Wilson, Angela [corrected to Brooks-Wilson, Angela].

23.

Predictive value of symptoms for early detection of ovarian cancer.

Rossing MA, Wicklund KG, Cushing-Haugen KL, Weiss NS.

J Natl Cancer Inst. 2010 Feb 24;102(4):222-9. doi: 10.1093/jnci/djp500. Epub 2010 Jan 28.

24.

ESR1/SYNE1 polymorphism and invasive epithelial ovarian cancer risk: an Ovarian Cancer Association Consortium study.

Doherty JA, Rossing MA, Cushing-Haugen KL, Chen C, Van Den Berg DJ, Wu AH, Pike MC, Ness RB, Moysich K, Chenevix-Trench G, Beesley J, Webb PM, Chang-Claude J, Wang-Gohrke S, Goodman MT, Lurie G, Thompson PJ, Carney ME, Hogdall E, Kjaer SK, Hogdall C, Goode EL, Cunningham JM, Fridley BL, Vierkant RA, Berchuck A, Moorman PG, Schildkraut JM, Palmieri RT, Cramer DW, Terry KL, Yang HP, Garcia-Closas M, Chanock S, Lissowska J, Song H, Pharoah PD, Shah M, Perkins B, McGuire V, Whittemore AS, Di Cioccio RA, Gentry-Maharaj A, Menon U, Gayther SA, Ramus SJ, Ziogas A, Brewster W, Anton-Culver H; Australian Ovarian Cancer Study Management Group; Australian Cancer Study (Ovarian Cancer), Pearce CL; Ovarian Cancer Association Consortium (OCAC).

Cancer Epidemiol Biomarkers Prev. 2010 Jan;19(1):245-50. doi: 10.1158/1055-9965.EPI-09-0729.

25.

Recreational physical activity and risk of epithelial ovarian cancer.

Rossing MA, Cushing-Haugen KL, Wicklund KG, Doherty JA, Weiss NS.

Cancer Causes Control. 2010 Apr;21(4):485-91. doi: 10.1007/s10552-009-9479-8. Epub 2009 Dec 2.

26.

Risk of epithelial ovarian cancer in relation to benign ovarian conditions and ovarian surgery.

Rossing MA, Cushing-Haugen KL, Wicklund KG, Doherty JA, Weiss NS.

Cancer Causes Control. 2008 Dec;19(10):1357-64. doi: 10.1007/s10552-008-9207-9. Epub 2008 Aug 14.

27.

Analgesic drug use and risk of epithelial ovarian cancer.

Hannibal CG, Rossing MA, Wicklund KG, Cushing-Haugen KL.

Am J Epidemiol. 2008 Jun 15;167(12):1430-7. doi: 10.1093/aje/kwn082. Epub 2008 Apr 4.

PMID:
18390840
28.

Coffee, tea, colas, and risk of epithelial ovarian cancer.

Song YJ, Kristal AR, Wicklund KG, Cushing-Haugen KL, Rossing MA.

Cancer Epidemiol Biomarkers Prev. 2008 Mar;17(3):712-6. doi: 10.1158/1055-9965.EPI-07-2511.

29.

Characteristics related to the maternal intrauterine environment and risk of epithelial ovarian cancer.

Rossing MA, Cushing-Haugen KL, Doherty JA, Wicklund KG.

Ann Epidemiol. 2008 May;18(5):411-5. doi: 10.1016/j.annepidem.2007.11.015. Epub 2008 Feb 8.

30.

Relationship between menopausal hormone therapy and risk of ductal, lobular, and ductal-lobular breast carcinomas.

Li CI, Malone KE, Porter PL, Lawton TJ, Voigt LF, Cushing-Haugen KL, Lin MG, Yuan X, Daling JR.

Cancer Epidemiol Biomarkers Prev. 2008 Jan;17(1):43-50. doi: 10.1158/1055-9965.EPI-07-0558. Erratum in: Cancer Epidemiol Biomarkers Prev. 2009 Oct;18(10):2803.

31.

Menopausal hormone therapy and risk of epithelial ovarian cancer.

Rossing MA, Cushing-Haugen KL, Wicklund KG, Doherty JA, Weiss NS.

Cancer Epidemiol Biomarkers Prev. 2007 Dec;16(12):2548-56.

32.

Cigarette smoking and risk of epithelial ovarian cancer.

Rossing MA, Cushing-Haugen KL, Wicklund KG, Weiss NS.

Cancer Causes Control. 2008 May;19(4):413-20. Epub 2007 Dec 15.

PMID:
18080774
33.

Long-term use of postmenopausal estrogen and progestin hormone therapies and the risk of endometrial cancer.

Doherty JA, Cushing-Haugen KL, Saltzman BS, Voigt LF, Hill DA, Beresford SA, Chen C, Weiss NS.

Am J Obstet Gynecol. 2007 Aug;197(2):139.e1-7.

PMID:
17689625
34.

Endometrial cancer risk in estrogen users after switching to estrogen-progestin therapy.

Chubak J, Doherty JA, Cushing-Haugen KL, Voigt LF, Saltzman BS, Hill DA, Beresford SA, Weiss NS.

Cancer Causes Control. 2007 Nov;18(9):1001-7. Epub 2007 Jul 25.

PMID:
17653829
35.

Risk of functional ovarian cyst: effects of smoking and marijuana use according to body mass index.

Holt VL, Cushing-Haugen KL, Daling JR.

Am J Epidemiol. 2005 Mar 15;161(6):520-5.

PMID:
15746468
36.

Body mass index, weight, and oral contraceptive failure risk.

Holt VL, Scholes D, Wicklund KG, Cushing-Haugen KL, Daling JR.

Obstet Gynecol. 2005 Jan;105(1):46-52.

PMID:
15625141
37.

Postmenopausal estrogen and progestogen therapy and the risk of uterine leiomyomas.

Reed SD, Cushing-Haugen KL, Daling JR, Scholes D, Schwartz SM.

Menopause. 2004 Mar-Apr;11(2):214-22.

PMID:
15021452
38.

Relation between use of antihypertensive medications and risk of breast carcinoma among women ages 65-79 years.

Li CI, Malone KE, Weiss NS, Boudreau DM, Cushing-Haugen KL, Daling JR.

Cancer. 2003 Oct 1;98(7):1504-13.

39.

Oral contraceptives, tubal sterilization, and functional ovarian cyst risk.

Holt VL, Cushing-Haugen KL, Daling JR.

Obstet Gynecol. 2003 Aug;102(2):252-8.

PMID:
12907096
40.

Relationship between long durations and different regimens of hormone therapy and risk of breast cancer.

Li CI, Malone KE, Porter PL, Weiss NS, Tang MT, Cushing-Haugen KL, Daling JR.

JAMA. 2003 Jun 25;289(24):3254-63.

PMID:
12824206
41.

Hormone replacement therapy regimens and breast cancer risk(1).

Weiss LK, Burkman RT, Cushing-Haugen KL, Voigt LF, Simon MS, Daling JR, Norman SA, Bernstein L, Ursin G, Marchbanks PA, Strom BL, Berlin JA, Weber AL, Doody DR, Wingo PA, McDonald JA, Malone KE, Folger SG, Spirtas R.

Obstet Gynecol. 2002 Dec;100(6):1148-58.

PMID:
12468157
42.

Human leukocyte antigen class II and cervical cancer risk: a population-based study.

Madeleine MM, Brumback B, Cushing-Haugen KL, Schwartz SM, Daling JR, Smith AG, Nelson JL, Porter P, Shera KA, McDougall JK, Galloway DA.

J Infect Dis. 2002 Dec 1;186(11):1565-74. Epub 2002 Nov 4.

PMID:
12447731
43.

Body weight and risk of oral contraceptive failure.

Holt VL, Cushing-Haugen KL, Daling JR.

Obstet Gynecol. 2002 May;99(5 Pt 1):820-7.

PMID:
11978293
44.

Human papillomavirus 16 and 18 L1 serology compared across anogenital cancer sites.

Carter JJ, Madeleine MM, Shera K, Schwartz SM, Cushing-Haugen KL, Wipf GC, Porter P, Daling JR, McDougall JK, Galloway DA.

Cancer Res. 2001 Mar 1;61(5):1934-40.

45.

Cimetidine use and risk of prostate and breast cancer.

Rossing MA, Scholes D, Cushing-Haugen KL, Voigt LF.

Cancer Epidemiol Biomarkers Prev. 2000 Mar;9(3):319-23.

Supplemental Content

Loading ...
Support Center